Clinical trials: in Paraguay
Microbiota
Effect of Consuming a Mango and Chia-based Beverage on Modulating the Intestinal Microbiota in Obese Children
This randomized clinical trial evaluates the effect of a mango and chia-based beverage on gut microbiota modulation in 100 Paraguayan children aged 8-16 years with obesity.
- Trial name
- NCT07529119
- Testing
- Mango juice, Mango and chia juice
- Where
- Paraguay
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Caaguazu
TBI (Traumatic Brain Injury)
Pediatric Guideline Adherence and Outcomes- Argentina
Pediatric traumatic brain injury (TBI) is the leading killer of children worldwide but effective treatments for TBI are limited.
- Trial name
- PEGASUS (NCT03896789)
- Testing
- PEGASUS Program for Care
- Where
- 16 sites in Argentina, Chile and 1 more
- Volunteers
- 505 people
- Sponsor
- University of Washington
Sepsis
Early Resuscitation in Paediatric Sepsis Using Inotropes
Septic shock in children still carries substantial mortality and morbidity. While resuscitation with 40-60 mL/kg intravenous fluid boluses remains a cornerstone of initial resuscitation, an increasing body of evidence indicates…
- Trial name
- ANDES-CHILD (NCT06478797)
- Testing
- Fluid, Adrenalin
- Where
- 4 sites in Argentina, Bolivia and 1 more
- Volunteers
- 40 people
- Sponsor
- NATALIA LOPERA MUNERA
Volatile Organic Compounds, Radiography
Tuberculosis Screening in Paraguayan Prisons
Two diagnostic tools for TB screening in high risk groups need additional assessment: the AeoNose™, an 'electronic nose device' for breath sampling, and digital chest X-ray (CXR) with computer aided detection with CAD4TB®…
- Trial name
- Prinose (NCT04407325)
- Testing
- electronic nose device, dig chest Xray with automated readings
- Where
- 2 sites in Paraguay
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Gaucher Disease, Type 1
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00430625
- Testing
- VPRIV ®,
- Where
- 5 sites in Argentina, Israel and 3 more
- Volunteers
- 25 people
- Sponsor
- Shire
Gaucher Disease, Type 1
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
The purpose of this study is to evaluate the long-term safety of every other week dosing of Gene-Activated® human glucocerebrosidase (GA-GCB, velaglucerase alfa) intravenously in patients with type 1 Gaucher disease.
- Trial name
- NCT00635427
- Testing
- VPRIV®
- Where
- 21 sites in United States, Argentina and 9 more
- Volunteers
- 95 people
- Sponsor
- Shire
Gaucher Disease, Type 1
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00553631
- Testing
- velaglucerase alfa, imiglucerase
- Where
- 11 sites in United States, Argentina and 7 more
- Volunteers
- 34 people
- Sponsor
- Shire
Childhood Obesity
Effect of a Physical Activity and Nutrition Education Intervention on Obesity Prevalence in Schoolchildren
Childhood obesity is a major global public health problem. Several strategies have been implemented to reduce the high prevalence, the most cost-effective of which were those that focused on the school environment.
- Trial name
- NCT04905966
- Testing
- Nutrition education and Physical activity intervention
- Where
- Paraguay
- Volunteers
- 1,568 people
- Sponsor
- Patricia Celestina Ríos Mujica
Gaucher Disease
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase alfa in untreated subjects (2 to <18 years old) with Gaucher disease randomly assigned to treatment with one of two doses, 30 or 60…
- Trial name
- NCT01132690
- Testing
- Taliglucerase alfa
- Where
- 3 sites in Israel, Paraguay and 1 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
Gaucher Disease
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to <18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols…
- Trial name
- NCT01411228
- Testing
- Taliglucerase alfa
- Where
- 3 sites in Israel, Paraguay and 1 more
- Volunteers
- 15 people
- Sponsor
- Pfizer
Respiratory Distress Syndrome
Early CPAP in Respiratory Distress Syndrome
The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.
- Trial name
- NCT00368680
- Testing
- Early Bubble CPAP
- Where
- 14 sites in Argentina, Chile and 3 more
- Volunteers
- 256 people
- Sponsor
- Pontificia Universidad Catolica de Chile